Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
BMC Complement Med Ther ; 23(1): 294, 2023 Aug 22.
Artigo em Inglês | MEDLINE | ID: mdl-37608290

RESUMO

BACKGROUND: Amyloid-ß1-42 (Aß1-42) plays an essential role in the development of the early stage of Alzheimer's disease (AD). Asiatic acid (AA), an active compound in Centella asiatica L, exhibit neuroprotective properties in previous studies. Due to its low bioavailability, the nose-to-brain delivery technique was used to enhance AA penetration in the brain. In this study, AA was also loaded in solid lipid nanoparticles (SLNs) as a strategy to increase its absorption in the nasal cavity. METHODS: Memory impairment was induced via direct intracerebroventricular injection of Aß1-42 oligomer into mouse brain. The neuroprotective effect and potential underlying mechanisms were investigated using several memory behavioral examinations and molecular techniques. RESULTS: The intranasal administration of AA in SLNs attenuated learning and memory impairment induced by Aß1-42 in Morris water maze and novel object recognition tests. AA significantly inhibited tau hyperphosphorylation of pTau-S396 and pTau-T231 and prevented astrocyte reactivity and microglial activation in the hippocampus of Aß1-42-treated mice. It is also decreased the high levels of IL-1ß, TNF-α, and malondialdehyde (MDA) in mouse brain. CONCLUSIONS: These results suggested that nose-to-brain delivery of AA in SLNs could be a promising strategy to treat the early stage of AD.


Assuntos
Doença de Alzheimer , Fármacos Neuroprotetores , Animais , Camundongos , Peptídeos beta-Amiloides/toxicidade , Fármacos Neuroprotetores/farmacologia , Encéfalo , Doença de Alzheimer/tratamento farmacológico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...